Charles River Laboratories International (NYSE:CRL) Price Target Lowered to $190.00 at The Goldman Sachs Group

Charles River Laboratories International (NYSE:CRL) had its price target decreased by The Goldman Sachs Group from $220.00 to $190.00 in a research report report published on Thursday morning,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the medical research company’s stock.

Other equities analysts have also issued reports about the company. Citigroup lowered Charles River Laboratories International from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $215.00 to $175.00 in a research report on Tuesday, October 1st. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Bank of America cut their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Redburn Atlantic assumed coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 price objective for the company. Finally, StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $204.38.

Charles River Laboratories International Trading Down 0.9 %

Shares of NYSE CRL opened at $166.75 on Thursday. Charles River Laboratories International has a fifty-two week low of $160.85 and a fifty-two week high of $275.00. The firm has a market capitalization of $8.53 billion, a P/E ratio of 20.87, a P/E/G ratio of 5.97 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The company’s 50 day simple moving average is $187.21 and its 200 day simple moving average is $197.51.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same quarter in the prior year, the business posted $2.72 EPS. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. On average, analysts predict that Charles River Laboratories International will post 10.18 EPS for the current year.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

Several hedge funds have recently modified their holdings of CRL. American Century Companies Inc. boosted its position in Charles River Laboratories International by 4.6% during the second quarter. American Century Companies Inc. now owns 6,556 shares of the medical research company’s stock valued at $1,354,000 after purchasing an additional 291 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in shares of Charles River Laboratories International by 74.5% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 4,031 shares of the medical research company’s stock valued at $833,000 after buying an additional 1,721 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Charles River Laboratories International in the 2nd quarter valued at approximately $124,000. ProShare Advisors LLC grew its stake in shares of Charles River Laboratories International by 6.2% in the second quarter. ProShare Advisors LLC now owns 9,975 shares of the medical research company’s stock valued at $2,061,000 after buying an additional 583 shares in the last quarter. Finally, Public Sector Pension Investment Board increased its holdings in Charles River Laboratories International by 77.8% during the second quarter. Public Sector Pension Investment Board now owns 1,982 shares of the medical research company’s stock worth $409,000 after buying an additional 867 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).